Acambis delivers good progress towards strategic goals - Press Releases

Acambis delivers good progress towards strategic goals
10 May 2005
Cambridge, UK and Cambridge, Massachusetts ? Acambis plc (?Acambis') (LSE: ACM, NASDAQ: ACAM) announces its results for the first quarter ended 31 March 2005.
Key points
> Acquisition of strategically important lyophilisation and fill/finish facility announced today (see separate news release)
> Smallpox vaccine franchise update:
- MVA3000 attenuated smallpox vaccine Phase l trial results in line with expectations: 97% seroconversion rate at the highest dose level
- Draft Request for Proposals for US Government attenuated smallpox vaccine stockpiling contract expected shortly
> Research and development update:
- ChimeriVax-JE: Bridging trial completed; serology analysis underway. Duration of immunity study provides supporting data for ChimeriVax-JE as a single-dose vaccine
- ChimeriVax-West Nile vaccine Phase I trial results reinforce earlier published data. 100% and 96% seroconversion at the low and high dose levels, respectively; plans for next trial underway
- C. difficile Phase l trials to be initiated in the next few weeks
> First results reported under International Financial Reporting Standards
Gordon Cameron, Chief Executive Officer of Acambis, commented:
?Acambis has seen good progress since the beginning of the year with the clinical pipeline moving forward very much in line with our expectations. We have also announced today the acquisition of a fill/finish facility in the US, which is a significant step towards achieving our strategic goals.
?Revenues in the period reflected the existing ACAM2000 US Government contract nearing its successful completion. We anticipate a busy period of newsflow through the second half of the year. In particular we look forward to hearing back from the US Government on our warm-base manufacturing proposal and the anticipated contract to supply MVA smallpox vaccine.'